Superior Planning, LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Superior Planning, LLC’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23.4K	Buy	+75	New	+$22.2K	0.01%	633

Other funds holding LGND

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Superior Planning, LLC's LGND Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2026: 75 shares worth $23.4K. The stake represents 0.01% of the portfolio and ranks #633 among its holdings.

294 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Superior Planning, LLC held 75 shares of Ligand Pharmaceuticals worth $23.4K as of Q3 2026.
Ligand Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Ligand Pharmaceuticals made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #633 holding.
294 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.